Difference between revisions of "Colon cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 1: Line 1:
 +
{{TOC limit|limit=3}}
 +
 
==Adjuvant therapy==
 
==Adjuvant therapy==
  
Line 7: Line 9:
  
 
Two different schedules have been used:
 
Two different schedules have been used:
−
#'''Q4weeks x 3 cycles, then Q5weeks x 3 cycles'''
+
#'''4-week cycles x 3 cycles, then 5-week cycles x 3 cycles'''
−
#'''Q4weeks x 6 cycles'''
+
#'''4-week cycles x 6 cycles'''
  
 
====References====
 
====References====
Line 21: Line 23:
 
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV push 1 hour after start of leucovorin weekly x 6 weeks
 
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV push 1 hour after start of leucovorin weekly x 6 weeks
  
−
'''Q8weeks x 4 cycles'''
+
'''8-week cycles x 4 cycles'''
  
 
====References====
 
====References====
Line 32: Line 34:
 
*[[Capecitabine (Xeloda)]] 1250 mg/m2 PO BID days 1-14
 
*[[Capecitabine (Xeloda)]] 1250 mg/m2 PO BID days 1-14
  
−
'''Q21days x 8 cycles'''
+
'''21-day cycles x 8 cycles'''
  
 
====References====
 
====References====
Line 43: Line 45:
 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours on weeks 1, 3, 5; given prior to 5-FU and leucovorin
 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours on weeks 1, 3, 5; given prior to 5-FU and leucovorin
  
−
'''Q8weeks x 3 cycles'''
+
'''8-week cycles x 3 cycles'''
  
 
====References====
 
====References====
Line 54: Line 56:
 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 in 250 mL of 5% dextrose IV over 2 hours concurrent with leucovorin day 1
 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 in 250 mL of 5% dextrose IV over 2 hours concurrent with leucovorin day 1
  
−
'''Q14days x 12 cycles'''
+
'''14-day cycles x 12 cycles'''
  
 
====References====
 
====References====
Line 62: Line 64:
 
# Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. [http://jco.ascopubs.org/content/26/12/2006.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18421053 PubMed]
 
# Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. [http://jco.ascopubs.org/content/26/12/2006.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18421053 PubMed]
  
−
===modified FOLFOX 6===
+
===mFOLFOX 6===
 
====Regimen====
 
====Regimen====
 
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
Line 68: Line 70:
 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours day 1
 
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours day 1
  
−
'''Q14days x 12 cycles'''
+
'''14-day cycles x 12 cycles'''
  
 
====References====
 
====References====
−
# Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6.
+
# Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. [http://www.pieronline.jp/content/article/0385-0684/34020/203 link to original article (Japanese)] [http://www.ncbi.nlm.nih.gov/pubmed/17301527 PubMed]
−
[http://www.pieronline.jp/content/article/0385-0684/34020/203 link to original article (Japanese)] [http://www.ncbi.nlm.nih.gov/pubmed/17301527 PubMed]
 
  
 
===FULV===
 
===FULV===
Line 79: Line 80:
 
*[[Folinic acid (Leucovorin)]] 500 mg/m2 IV over 2 hours weekly x 6
 
*[[Folinic acid (Leucovorin)]] 500 mg/m2 IV over 2 hours weekly x 6
  
−
'''Q8weeks x 3 cycles'''
+
'''8-week cycles x 3 cycles'''
  
 
====References====
 
====References====
Line 90: Line 91:
 
*No food for 1 hour before and after each dose of medication.
 
*No food for 1 hour before and after each dose of medication.
  
−
'''Q5weeks x 5 cycles'''
+
'''5-week cycles x 5 cycles'''
  
 
====References====
 
====References====
Line 100: Line 101:
 
*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours day 1
 
*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours day 1
  
−
'''Q21days x 8 cycles'''
+
'''21-day cycles x 8 cycles'''
 +
 
 
====References====
 
====References====
 
# Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. [http://jco.ascopubs.org/content/25/1/102.long link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/17194911 PubMed]
 
# Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. [http://jco.ascopubs.org/content/25/1/102.long link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/17194911 PubMed]
Line 107: Line 109:
  
 
==Advanced or metastatic disease==
 
==Advanced or metastatic disease==
 +
===mFOLFOX 6===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over 2 hours day 1
 +
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
# Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. [http://www.pieronline.jp/content/article/0385-0684/34020/203 link to original article (Japanese)] [http://www.ncbi.nlm.nih.gov/pubmed/17301527 PubMed]
 +
 +
===mFOLFOX 6 & Bevacizumab (Avastin)===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over 2 hours day 1
 +
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours day 1
 +
*[[Bevacizumab (Avastin)]] 5 mg/kg IV day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
 +
===mFOLFOX 6 & Panitumumab (Vectibix)===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over 2 hours day 1
 +
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours day 1
 +
*[[Panitumumab (Vectibix)]] 6 mg/kg IV over 60 minutes day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
 +
===CapeOX===
 +
CapeOX: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin
 +
 +
====Regimen====
 +
*[[Capecitabine (Xeloda)]] 850-1000 (however, lower dosages often used) mg/m2 PO BID on days 1-14
 +
*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours on day 1
 +
 +
'''21-day cycles'''
 +
 +
====References====
 +
 +
===CapeOX & Bevacizumab (Avastin)===
 +
CapeOX: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin
 +
 +
====Regimen====
 +
*[[Capecitabine (Xeloda)]] 850-1000 (however, lower dosages often used) mg/m2 PO BID on days 1-14
 +
*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours on day 1
 +
*[[Bevacizumab (Avastin)]] 7.5 mg/kg IV over 15 minutes on day 1
 +
 +
'''21-day cycles'''
 +
 +
====References====
 +
 +
===FOLFIRI===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
 +
*[[Irinotecan (Camptosar)]] 180 mg/m2 IV over 30-90 minutes day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
 +
===FOLFIRI & Bevacizumab (Avastin)===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
 +
*[[Irinotecan (Camptosar)]] 180 mg/m2 IV over 30-90 minutes day 1
 +
*[[Bevacizumab (Avastin)]] 5 mg/kg IV day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
 +
===FOLFIRI & Cetuximab (Erbitux)===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
 +
*[[Irinotecan (Camptosar)]] 180 mg/m2 IV over 30-90 minutes day 1
 +
*EITHER [[Cetuximab (Erbitux)]] 400 mg/m2 IV over 2 hours on cycle 1 day 1, then 250 mg/m2 IV over 60 minutes on day 8 of cycle 1; then on subsequent cycles, [[Cetuximab (Erbitux)]] 250 mg/m2 IV over 60 minutes on days 1 & 8
 +
*OR [[Cetuximab (Erbitux)]] 500 mg/m2 IV over 2 hours on day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
 +
===FOLFIRI & Panitumumab (Vectibix)===
 +
====Regimen====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
 +
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
 +
*[[Irinotecan (Camptosar)]] 180 mg/m2 IV over 30-90 minutes day 1
 +
*[[Panitumumab (Vectibix)]] 6 mg/kg IV over 60 minutes day 1
 +
 +
'''14-day cycles'''
 +
 +
====References====
 +
 +
===Capecitabine (Xeloda)===
 +
====Regimen====
 +
*[[Capecitabine (Xeloda)]] 850-1250 mg/m2 PO BID days 1-14
 +
 +
'''21-day cycles'''
 +
 +
====References====
 +
 +
===Capecitabine (Xeloda) & Bevacizumab (Avastin)===
 +
====Regimen====
 +
*[[Capecitabine (Xeloda)]] 850-1250 mg/m2 PO BID days 1-14
 +
*[[Bevacizumab (Avastin)]] 7.5 mg/kg IV over 15 minutes on day 1
 +
 +
'''21-day cycles'''
 +
 +
====References====

Revision as of 18:34, 19 February 2012


Adjuvant therapy

5-FU & low-dose Leucovorin (Mayo Clinic regimen/LDLV)

Regimen

Two different schedules have been used:

  1. 4-week cycles x 3 cycles, then 5-week cycles x 3 cycles
  2. 4-week cycles x 6 cycles

References

  1. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997 Jan;15(1):246-50. link to original article (contains protocol) PubMed
  2. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. link to original article (contains protocol) PubMed
  3. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. link to original article (contains protocol) PubMed
  4. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article (contains protocol) PubMed

5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV)

Regimen

8-week cycles x 4 cycles

References

  1. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. link to original article (contains protocol) PubMed
  2. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. link to original article (contains protocol) PubMed
  3. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article (contains protocol) PubMed

Capecitabine (Xeloda)

Regimen

21-day cycles x 8 cycles

References

  1. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. link to original article (contains protocol) PubMed

FLOX

Regimen

8-week cycles x 3 cycles

References

  1. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30. link to original article (contains protocol) PubMed

FOLFOX 4

Regimen

  • Fluorouracil (5-FU) 400 mg/m2 IV bolus, then 600 mg/m2/day IV continuous infusion over 22 hours; both bolus and continuous infusion given on days 1 & 2
  • Folinic acid (Leucovorin) 200 mg/m2 IV over 2 hours before 5-FU on days 1 and 2
  • Oxaliplatin (Eloxatin) 85 mg/m2 in 250 mL of 5% dextrose IV over 2 hours concurrent with leucovorin day 1

14-day cycles x 12 cycles

References

  1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938-47. link to original article (contains protocol) PubMed
  2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51. link to original article (contains protocol) PubMed
  3. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006 Sep 1;24(25):4085-91. link to original article PubMed
  4. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. link to original article PubMed

mFOLFOX 6

Regimen

14-day cycles x 12 cycles

References

  1. Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. link to original article (Japanese) PubMed

FULV

Regimen

8-week cycles x 3 cycles

References

  1. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30. link to original article (contains protocol) PubMed

UFT & leucovorin

Regimen

5-week cycles x 5 cycles

References

  1. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. link to original article (contains protocol) PubMed

XELOX (CapeOx)

Regimen

21-day cycles x 8 cycles

References

  1. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article (contains protocol) PubMed
  2. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. link to original article (contains protocol) PubMed


Advanced or metastatic disease

mFOLFOX 6

Regimen

14-day cycles

References

  1. Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. link to original article (Japanese) PubMed

mFOLFOX 6 & Bevacizumab (Avastin)

Regimen

14-day cycles

References

mFOLFOX 6 & Panitumumab (Vectibix)

Regimen

14-day cycles

References

CapeOX

CapeOX: Capecitabine, OXaliplatin

Regimen

21-day cycles

References

CapeOX & Bevacizumab (Avastin)

CapeOX: Capecitabine, OXaliplatin

Regimen

21-day cycles

References

FOLFIRI

Regimen

14-day cycles

References

FOLFIRI & Bevacizumab (Avastin)

Regimen

14-day cycles

References

FOLFIRI & Cetuximab (Erbitux)

Regimen

14-day cycles

References

FOLFIRI & Panitumumab (Vectibix)

Regimen

14-day cycles

References

Capecitabine (Xeloda)

Regimen

21-day cycles

References

Capecitabine (Xeloda) & Bevacizumab (Avastin)

Regimen

21-day cycles

References

Retrieved from "https://hemonc.org/w/index.php?title=Colon_cancer&oldid=843"